Kathleen Skarvan Sells 38,954 Shares of Electromed, Inc. (NYSE:ELMD) Stock

Electromed, Inc. (NYSE:ELMD) Director Kathleen Skarvan sold 38,954 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $29.28, for a total value of $1,140,573.12. Following the completion of the sale, the director now directly owns 32,622 shares of the company’s stock, valued at $955,172.16. The trade was a 54.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kathleen Skarvan also recently made the following trade(s):

• On Friday, February 14th, Kathleen Skarvan sold 8,640 shares of Electromed stock. The shares were sold at an average price of $32.25, for a total value of $278,640.00.

Electromed Stock Performance

Shares of ELMD opened at $27.97 on Friday. The firm has a market capitalization of $239.42 million, a P/E ratio of 37.29 and a beta of 0.33. Electromed, Inc. has a 52 week low of $13.74 and a 52 week high of $35.56. The stock has a 50 day moving average price of $31.40 and a two-hundred day moving average price of $25.26.

Institutional Investors Weigh In On Electromed

Several institutional investors have recently bought and sold shares of ELMD. Arrowstreet Capital Limited Partnership lifted its stake in Electromed by 261.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 114,579 shares of the company’s stock valued at $3,386,000 after acquiring an additional 82,839 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Electromed in the fourth quarter valued at about $1,760,000. Sowell Financial Services LLC bought a new position in shares of Electromed during the fourth quarter valued at about $1,518,000. Lazard Asset Management LLC boosted its holdings in Electromed by 19,860.8% during the fourth quarter. Lazard Asset Management LLC now owns 47,906 shares of the company’s stock worth $1,415,000 after purchasing an additional 47,666 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in Electromed in the 4th quarter worth about $1,255,000. Institutional investors own 40.82% of the company’s stock.

Analyst Ratings Changes

ELMD has been the topic of a number of recent research reports. B. Riley initiated coverage on Electromed in a report on Thursday. They issued a “buy” rating and a $38.00 target price on the stock. StockNews.com lowered shares of Electromed from a “strong-buy” rating to a “buy” rating in a research note on Wednesday.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.